Companies Dominating the Rituximab Landscape
- Amgen Inc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Henlius Biotech, Inc.
- Nordic Nanovector ASA
- Biocon Biologics Ltd
- Pfizer Inc.
- Chugai Pharmaceuticals
- Zenyaku Kogyo Co. Ltd,
- SymBio Pharmaceuticals
- Daiichi Sankyo
- Kyowa Kirin Co. Ltd
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of rituximab is estimated at USD 5.11 billion.
The rituximab market size was over USD 4.03 billion in 2024 and is anticipated to cross USD 27.13 billion by 2037, witnessing more than 15.8% CAGR during the forecast period i.e., between 2025-2037. Increasing demand for monoclonal antibodies, increasing collaborations for the development of new products and investment in healthcare sector will drive the market growth.
North America industry is anticipated to dominate majority revenue share of 45% by 2037, fuelled by increased government spending on cancer research as well as the presence of major pharmaceutical companies in the region.
The major players in the market are Amgen Inc, Henlius Biotech, Inc., Nordic Nanovector ASA, Biocon Biologics Ltd, Pfizer Inc., Chugai Pharmaceuticals, Zenyaku Kogyo Co. Ltd, SymBio Pharmaceuticals, Daiichi Sankyo, Kyowa Kirin Co. Ltd
